Hot Features
Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.
NeuroSense Secures Key FDA Meeting to Advance its Phase 3 ALS Trial and NDA Submission PR Newswire CAMBRIDGE, Mass., Oct. 28, 2024 Meeting discussion to focus on finalizing Phase 3 study design...
New Analysis Shows PrimeC Significantly Improves Key miRNAs in ALS Patients PR Newswire CAMBRIDGE, Mass., Oct. 24, 2024 Groundbreaking PARADIGM Trial Offers New Hope for ALS Treatment CAMBRIDGE...
NeuroSense Advances Plans for Early Commercialization of Groundbreaking ALS Treatment in Canada, Provides Further Updates PR Newswire CAMBRIDGE, Mass., Oct. 15, 2024 Dossier submission planned...
NeuroSense Therapeutics Plans to File for Early Commercialization of ALS Treatment in Canada PR Newswire CAMBRIDGE, Mass., Oct. 9, 2024 The preparations for the regulatory submission for early...
NeuroSense Therapeutics Announces Acceptance of Two PrimeC Abstracts at the 2024 NEALS Annual Meeting PR Newswire CAMBRIDGE, Mass., Oct. 7, 2024 CAMBRIDGE, Mass., Oct. 7, 2024 /PRNewswire/...
NeuroSense Therapeutics Granted Key U.S. Patent for Novel PrimeC Formulation, its Lead Asset for ALS and Alzheimer's PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 The Company's intellectual...
NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule PR Newswire CAMBRIDGE, Mass., Sept. 24, 2024 CAMBRIDGE, Mass., Sept. 24, 2024 /PRNewswire/ -- NeuroSense Therapeutics...
NeuroSense Therapeutics Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire CAMBRIDGE, Mass., Aug. 30, 2024 CAMBRIDGE, Mass., Aug. 30, 2024 /PRNewswire/ -- NeuroSense...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.07 | -5.38461538462 | 1.3 | 1.35 | 1.26 | 70899 | 1.31958953 | CS |
| 4 | 0.09 | 7.89473684211 | 1.14 | 1.4 | 1.04 | 181431 | 1.27605442 | CS |
| 12 | 0.4013 | 48.4252443586 | 0.8287 | 1.455 | 0.6729 | 244793 | 1.07862151 | CS |
| 26 | 0.09 | 7.89473684211 | 1.14 | 1.5 | 0.512 | 264335 | 0.98978374 | CS |
| 52 | 0.749 | 155.717255717 | 0.481 | 2.33 | 0.47 | 396735 | 1.13110655 | CS |
| 156 | -3.32 | -72.967032967 | 4.55 | 8.18 | 0.4 | 996418 | 3.42912862 | CS |
| 260 | -3.32 | -72.967032967 | 4.55 | 8.18 | 0.4 | 996418 | 3.42912862 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
